Veröffentlichungen

Originalarbeiten

Diese Publikationen weisen zum Einen auf die nationale und internationale Reputation unserer Praxis hin, aber auch darauf, dass unsere Patienten aufgrund der kontinuierlichen wissenschaftlichen Betätigung versichert sein können, stets mit Therapien nach aktuellstem Wissensstand und höchsten qualitativen Standards behandelt zu werden.

  1. Fenchel K, Bergmann L., Jahn B., Mitrou P.S.: Modulation of adhesion molecules in patients with AML during immunotherapy with interleukin-2. In: Haematology and Blood Transfusion. Acute leukemias IV (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1993), 90-95
  2. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Upregulation of adhesion molecules byimmunotherapy as a mechanism of cytotoxicity in renal cell cancer, malignant melanoma, and acute myelocytic leukemia. In: Bergmann L., Mitrou PS. (eds.) Contributions to Oncology: Cytokines in Cancer Therapy. Karger Verlag, Basel (1994), 336-346
  3. Fenchel K., Wijermans P., Mitrou P.S., Hoelzer D., Bergmann L.: Fludarabine is an effective agent in immunocytic lymphoma. Onkologie 17 (1994), 508-513
  4. Fenchel K., Heller C., Weidmann E., Wörmann B., Brieger J., Ganser A., Mitrou P.S., Bergmann L., Hoelzer D.: Expression of CD7 and CD15 on leukemic blasts are prognostic parameters in patients with acute myelocytic leukemia-irrelevance of CD34 Acute leukemias V (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1995) 536-541
  5. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical experience with fludarabine and it’s immunosuppressive effects in pretreated chronic lymphocytic Leuk. Lymphoma, 18 (1995) 485-492
  6. Bergmann L., Fenchel K., Jahn B., Mitrou P.S., Hoelzer D.: Immunosuppressive effects and clinical response of fludarabine in refractory chronic lymphocytic leukemia. Ann. Oncol. 4 (1993), 371-375
  7. Fenchel K.: Hämatologie-Onkologie. In: Almeling M., Böhm F. (eds.) Tauchmedizin. Ecomed Verlag, 1998 chapter II 7.4.7, 1-15
  8. Fenchel K., Karthaus M.: Cytotoxic Drug Extravasation. Antibiotics and Chemotherapy Vol. 50, Karger Verlag (1999) 144-148
  9. Göke B., Fenchel K., Knobloch S., Arnold R., Adler G.: Increased CCK-response to proteinase inhibitor feeding after induction of pancreatic hypertrophy in rats. Pancreas (1988) 3; 5: 576-579
  10. Fenchel K., Karthaus M.: Zytostatika Paravasate- Prävention und Therapie. MMW, 2001, 3/4: 44-46
  11. Bergmann L., Fenchel K., Neugebauer T., Jahn B., Enzinger HM., Jonas D., Mitrou P.S.: Daily alternating administration of interferon-alpha and interleukin-2 bolus infusion in two different dose levels in metastatic renal cell cancer – results of two phase II studies. In: Bergmann L., Mitrou P.S. (eds.) Contributions to Oncology: Cytokines in Cancer Therapy. Karger Verlag, Basel (1994), 201-210
  12. Bergmann L., Fenchel K., Enzinger HM., Weidmann E., Jahn B., Jonas D., Mitrou P.S.: Daily alternating application of high dose interferon-alpha and interleukin-2 bolus infusions in metastatic renal cell carcinoma. Cancer, 72 (1993), 1733-1742
  13. Kemkes-Matthes B., Fenchel K., Matzdorff A.: Gerinnungsstörungen als Notfall bei onkologischen Patienten. Der Onkologe (1999) 5, 1083-1089
  14. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L: The amplification of the Wilms tumor gene (wt-1) mRNA using the polymerase chain reaction technique may enable sensitive detection of small blast populations in AML. Acute leukemias V (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1995)
  15. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: The expression of the Wilms tumor gene in acute human leukemias as a possible marker for blast cells. Leukemia (1994), 8 (12); 2138-2143
  16. Hauck EW., Schmelz HU., Diemer T., Hackstein N., Fenchel K., Weidner W., Knoblauch B.: Epitheloid sarcoma of the penis – a rare differential diagnosis of Peyronie’s diagnose. Int J Impot Res. 2003 Oct;15(5):378-82.
  17. Jahn B., Bergmann L, Weidmann E., Brieger J., Fenchel K., Schwulera U., Hoelzer D., Mitrou P.S.: Bone marrow derived T cell clones of previously untreated acute myelocytic leukemia exhibit blast directed autologous cytotoxicity. Leuk. Res. (1995), 19 (2); 73-82
  18. Bergmann L., Weidmann E., Enzinger HM., Fenchel K., Jonas D., Mitrou P.S.: Interleukin-2 and interferon-alpha2b as a daily alternating schedule in advanced renal cell cancer – preliminary results of a phase-II study. World J. Urol., 9 (1991), 215-218
  19. Weidmann E., Brieger J., Fenchel K., Hoelzer D., Bergmann L., Mitrou P.S.: IL-2 receptor alpha, beta, and gamma chains expressed on blasts of acute myelocytic leukemia may not be functional. Acute leukemias V (Hiddemann et al., ed.), Springer Verlag, Heidelberg (1995)
  20. Jahn B., Brieger J., Fenchel K., Bergmann L., Mitrou PS.: In vivo regulation of transforming growth factor-beta 1 mRNA in combined cytokine therapy: Interleukin-2 impairs interferon-alpha stimulated increase in transforming growth factor steady state mRNA levels. Cancer Immunol. Immunother. 38 (1994), 304-310
  21. Duensing S., Schuhknecht S., Fenchel K., Ganser A., Atzpodien J.: Inhibitory effects of Interleukin-12 (IL-12) on spontaneous in vitro apoptosis in B-chronic lymphocytic leukemia (B-CLL). Letter to Blood (1996)
  22. Borghardt E.J., Kirchertz E.J., Marten I., Fenchel K.: Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Transf. a. Sciences, Vol.19, pp. 5-7 (1998)
  23. Karthaus M., Südhoff T., Fenchel K., Egerer G., Kämpfe D., Ritter J., Franke A., Heil G., Peters G.: Interventional once daily administration of ceftriaxone in patients with hematological malignancies and febrile neutropenia. WMW 21 (1998), 481-487
  24. Karthaus M., Südhoff T., Fenchel K., Egerer G., Kämpfe D., Ritter J., Franke A., Heil G., Peters G.: Interventional once daily administration of cefriaxone in leukaemia and lymphoma patients with febrile neutropenia. Antibiotics and Chemotherapy Vol. 50, Karger Verlag (1999), 26-36
  25. Hackstein N., Fenchel K., Klett R., Woenckhaus J., Lommel D., Rau W.S.: Multifocal spondylitis after delivery as manifestation of chronic recurrent multifocal osteomyelitits (CRMO): Case report and literature review. Eur. Rad. 2001
  26. Wagner G, Fenchel K, Back W, Schulz A, Sachse MM.: Leukemia cutis – epidemiology, clinical presentation, and differential diagnoses. JDDG 2012 Jan;10(1):27-36. doi: 10.1111/j.1610-0387.2011.07842.x. Epub 2011 Nov 17
  27. Göhring K, Wolff J, Doppl W, Schmidt KL, Fenchel K, Pralle H, Sibelius U, Bux J.: Neutrophil CD177 (NB1 gp, HNA-2a) expression is increased in severe bacterial infections and polycythaemia vera. Br J Haematol. 2004 Jul;126(2):252-4
  28. Fenchel K, Karthaus M.: Cytostatic drug extravasation–are there new recommendations for therapeutic management? Wien Med Wochenschr. 2001;151(3-4):44-6.
  29. Fenchel K., Rahn S.: Hämatologie In: Tauchtauglichkeit (ed. Tetzlaff K. et al.) Gentner Verlag 2009, 182-201
  30. Wagner G, Fenchel K, Back W, Schulz A, Sachse MM.: Rückbildung Braf assoziierter Keratoakanthome durch Acitrein. JDDG 2014
  31. Dempke W., Fenchel K.: Targeted therapy in NSCLC- a double egded sword? (EJM 2014 accepted) Anticancer Res. 2015; 35:2503-12
  32. Fenchel K., Rahn S.: Hämatologie In: Tauchtauglichkeit (ed. Tetzlaff K. et al.) Gentner Verlag 2014, 277-295
  33. Sellmann L., Fenchel K. , Dempke W.: Improved overall survival following TKI treatment in advanced or metastatic NSCLC- The Holy Grail in cancer treatment? Transl Lung Cancer Res 2015; 4:223-7
  34. Dempke WCM., Sellmann L., Fenchel K.: Immunotherapies for NSCLC – are we cutting the Gordian helix? Anticancer Res 2015; 35:5745-57
  35. Fenchel K. , Sellmann L., Dempke WCM.: Overall survival in NSCLC- what is clinically meaningful? Transl Lung Cancer Res 2016; Vol 5, (1): 115-119
  36. Fenchel K.: Therapie mit Mikroorganismen In: Ratgeber unkonventionelle Krebstherapien (ed. K. Münstedt) ecomed Medizin Verlag 2003 269-276
  37. Dempke WCM., Fenchel K, Dale SP.:Pembrolizumab as first-line treatment for non-small cell lung cancer—a game changer? Transl Lung Cancer Res 2016; Vol 5, (5): 538-542
  38. Fenchel K, Dale SP, Dempke WC. Improved overall survival following tyrosine kinase inhibitor (TKI) treatment in NSCLC—are we making progress? Transl Lung Cancer Res 2016;5(4):373-376.
  39. Dempke WCM, Fenchel K, Uciechowski P, Dale SP:Second and third generation drugs for immuno-oncology treatment – the more the better? Eur J Cancer 2017 Mar;74:55-72. doi: 10.1016/j.ejca.2017.01.001. Epub 2017 Feb 10
  40. Dempke WCM, Dale SP., Fenchel K., Uciechowski P., Chevassut T.: Targeting Developmental Pathways –the Achilles Heel of Cancer? Oncology 2017; 93(4)
  41. Dempke WCM, Fenchel K.: Durvalumab for unresectable stage III non-small cell lung cancer – a small step or a big leap? Transl Lung Cancer Res 2018;7(Suppl 2):S153-S157
  42. Dempke WCM, Uciechowski P., Fenchel K., Chevassut T.: Targeting SHP-1,2 and SHIP pathways – a novel strategy for cancer treatment? Oncology 2018;95:257–269
  43. Dempke WCM, Fenchel K.: Treating epidermal growth factor receptor-mutated non-small cell lung cancer—is dacomitinib the winner? Transl Lung Cancer Res 2017;6(Suppl 1):S88-S91
  44. Dempke WCM, Dale SP., Fenchel K.: Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment—are we barking up the wrong tree? Transl Lung Cancer Res 2018;7(Suppl 3):S275-S279
  45. Manz, K.M., Fenchel, K., Eilers, A., Morgan J., Wittling K., Dempke WCM.: Efficacy and Safety of Approved First-Line Tyrosine Kinase Inhibitor Treatments in Metastatic Renal Cell Carcinoma: A Network Meta-Analysis Adv Ther 2020; 37, 730–744 https://doi.org/10.1007/s12325-019-01167-2
  46. Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Köberle, D; Welslau, M; Akhoundova, D; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Rhyner, G; Weide, R; Modest, DP; Fritsch, RM.: Retrospective analysis of treatment pathways in patients with BRAFV600E-mutant metastatic colorectal carcinoma – MORSECRC Submitted to: Anticancer Research 2021 EMID:5580e62dabd867e2
  47. Frost N., Christopoulos P., Kauffmann-Guerrero D., Stratmann J., Riedel R., Schaefer M., Alt J., Gütz S., Christoph D., Laack E., Faehling M., Fischer R., Fenchel K., Haen S., Heukamp L., Schulz C., Griesinger F.: Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: Results from the German early access program, Therapeutic Advances in Medical Oncology. January 2021. doi:10.1177/1758835920980558
  48. Dempke W, Fenchel K.: Has programmed cell death ligand-1 (PD-L1) MET an accomplice in non-small cell lung cancer (NSCLC)? A narrative review, Transl Lung Cancer Res 2021; Res 10: 2667-2682 (2021) http://dx.doi.org/10.21037/tlcr-21-124
  49. Dempke WCM, Fenchel K., Reuther S., Murphy MF: Durvalumab plus novel agents in NSCLC—a new COAST on the horizon? Transl Lung Cancer Res (in press 2022;
  50. Fenchel K., Fenchel S., Dempke W.: Moderne Therapie des M. Waldenström in Zeiten der Pandemie: How easy tasks can get complicated Haematooncology 2022, Transl Lung Cancer Res 2021; Res 10: 2667-2682 (2021) http://dx.doi.org/10.21037/tlcr-21-124
  51. Diessner J., Busch S., Fenchel K., Schröder J., Sieg K., Thill M.: Rezidivtherapie des fortgeschrittenen Ovarialkarzinoms: Welcher PARP-Inhibitor für welche Patientin? Eine Orientierungshilfe für die Praxis, Onkologie 2022;
  52. Cinetto F., Francisco I.E., Fenchel K., Montefusco V., Pluta A., Wolf H.M.: IVIG use in SID patients in press
  53. Wang SY., Holzhey T., Heyn S., Zehrfeld T., Fricke S., Hoffmann FA., Becker C., Braunert L., Edelmann T., Paulenz I., Hitzschke M., Flade F., Schwarzer A., Fenchel K., Franke GN., Vucinic V., Jentzsch M., Schwind S., Hell S., Backhaus D., Lange T., Niederwieser D., Scholz M., Platzbecker U., Pönisch W.: Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 newly diagnosed myeloma patients: a retrospective real‑world study. Journal of Cancer Research and Clinical Oncology https://doi.org/10.1007/s00432-022-04184-x
  54. Wacheck V., Fenchel K., Dempke W.: Targeting C797S mutations and beyond in non-small cell lung cancer – a strike of a genius? TCR-24-690 submitted
  55. Dempke W., Fenchel K., Waymack P.: Placenta Stem Cells: Biology and Clinical Applications. In: Textbook of Hematology, 2024 in press
  56. Dempke W., Fenchel K.: Targeting C797S mutations and beyond in non-small cell lung cancer—a mini-review. Transl Cancer Res 2024;13(11):6540-6549 |
  57. Dempke W., Fenchel K.: Targeting menin in relapsed or refractory acute myeloid leukaemias – where the rubber hits the road. AME Clinical Trials Review (ACTR-24-250)
  58. Dempke W., Fenchel K.: TET2 cascade: a novel regulator of chromatin structure and leukaemogenesis. Nature, Signal Transduction and Targeted Therapy SIGTRANS-15744R
  59. Dempke W., Winkler C., Reuther S., Bauer S., Priebe W.: Anthracycline induced Cardiotoxicity- are we about to clear this hurdle? Eur. J. Cancer Feb 2023, 185, DOI:10.1016/j.ejca.2023.02.019

Abstracts (Vorträge und Poster)

  1. Fenchel K., Bergmann L., Jahn B., Mitrou P.S., Hoelzer D.: Fludarabinmonophosphat in refractory chronic lymphocytic leukemia. Onkol. 14 Suppl. 2 (1991), 190 (Abstr. 546)
  2. Fenchel K., Bergmann L., Enzinger H., Jahn B., Weidmann E., Mitrou P.S.: Klinische Ergebnisse und biologische Effekte einer täglich alternierenden Therapie mit Interleukin-2 und Interferon-alpha beim fortgeschrittenen Nierenzellkarzinom. Onkol. 14 Suppl.2 (1991), 40 (Abstr. 112)
  3. Fenchel K., Bergmann L., Martin H., Jahn B., Mitrou P.S., Hoelzer D.: Clinical and biological effects of interleukin-2 as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologous bone marrow transplantation. Haematol. 76 Suppl. 4 (1991), 55 (Abstr. 209)
  4. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Modulation of LFA1-alpha, LFA1-beta, VLA1 and ICAM-1 in vivo by interleukin-2 and alpha-interferon. Cell adhesion molecules in cancer and inflammation, London, 11.-13.12.1991
  5. Fenchel K., Bergmann L, Jahn B., Mitrou P.S.: Up-regulation of LFA-1 alpa, LFA 1 beta, VLA-1, and ICAM-1 in vivo by interleukin-2 in patients with AML. Ann. Hematol. 64 Suppl. (1992), Abstr. 131
  6. Fenchel K., Jahn B., Bergman L., Mitrou P.S.: Effects of immunotherapy with interleukin-2 and alpha-interferon in patients with malignant melanoma, renal cell carcinoma and AML on adhesion molecules. 8. Frühjahrestagung Dtschl. Ges. Immunol., München, 9.-11.3.1992
  7. Fenchel K., Bergmann L., Eder M., Jahn B., Mitrou P.S.: Modulation of adhesion molecules in vivo by interleukin-2 in patients with AML. 2nd Eur.Soc.Annalyt.Cell. Pathol. (ESAC 2), Nijmwegen, NL, 17.-22.3.1992 Analyt. Cell.Pathol. (1992) 4; 3:155
  8. Fenchel K., Jahn B., Bergmann L., Mitrou P.S.: Upregulation of adhesion molecules by immunotherapy as a mechanism of cytotoxicity in renal cell cancer, malignant melanoma and AML. Onkol. 15 (1992), Suppl. 1, 27
  9. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Effectivity and toxicity of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia. J. Cancer Res. Clin. Oncol. 118 (1992), R104
  10. Fenchel K., Jahn B., Bergmann L., Mitrou P.S.: effects of adhesion molecules of immunotherapy with interleukin-2 and alpha-interferon in patients with malignant melanoma, renal cell cancer and AML. 8th International Congress of Immunology, Budapest, 23. – 28.8.1992
  11. Fenchel K., Gencic S., Jahn B., Mitrou P.S., Bergmann L.: Adhesion molecules during immunotherapy in patients with AML, renal cell cancer and malignant melanoma. 24th Congress Intern. Soc. Haematol., London, 23. – 27.8.1992
  12. Fenchel K., Jahn B., Mitrou P.S., Bergmann L.: Fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia – effectivity and immunosuppressive side effects. 24th Congress Intern. Soc. Haematol., London, 23. – 27.8.1992
  13. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia. Ann. Hematol. 65 Suppl. (1992), A53
  14. Fenchel K., Ernst W., Bergmann L., Jahn B., Ostermann M., Baum R.P., Mitrou P.S.: Complete remission of an allogeneic malignant melanoma acquired by kidney transplantation with immunotherapy of interleukin-2/alpha-Interferon. Ann. Hematol. 65 Suppl. (1992), A53
  15. Fenchel K., Gencic S., Jahn B., Mitrou P.S., Bergmann L.: Modulation of adhesion molecules by immunotherapy as a mechanism of cytotoxicity in AML, renal cell cancer, and malignant melanoma. Ann. Hematol. 65 Suppl. (1992), A53
  16. Fenchel K., Bergmann L., Neugebauer T., Enzinger H.M., Jahn B., Mitrou P.S., Hoelzer D.: Täglich alternierende Gabe von Interferon-alpha und Interleukin-2 beim metastasierten Nierenzellkarzinom. 6. Hessischer Krebskongress, Bad Homburg, 6. – 8.11.1992
  17. Fenchel K., Bergmann L., Jahn B., Mitrou P.S., Hoelzer D.: Effektivität und Toxizität von Fludarabin in der Behandlung der fortgeschrittenen chronisch lymphatischen Leukämie. 6. Hessischer Krebskongress, Bad Homburg, 6. – 8.11.1992
  18. Fenchel K., Ernst W., Bergmann L., Jahn B., Ostermann M., Baum R., Mitrou P.S.: Komplette Remission bei einem allogenen malignen Melanom durch IL-2/Interferon-alpha – eine Kasuistik. Med. Klinik 88 Suppl.2 (1993), 178
  19. Fenchel K., Bergmann L., Jahn B., Mitrou P.S.: Modulation of adhesion molecules during immunotherapy. 1. Tagung d. Arbeitskreises Adhäsionsmoleküle der Dtsch. Ges. f. Immunologie, Heidelberg, 11. – 12.2.1993
  20. Fenchel K., Bergmann L., Brieger J., Jahn B., Mitrou P.S.: Modulation of adhesion molecules (CAM) on lymphocytes by IL-2 and expression of CAM on blasts in patients with AML. Proc. Am. Ass. Cancer Res., 34 (1993) 471 (Abstr. 2811)
  21. Fenchel K., Brieger J., Weidmann E., Mitrou P.S., Bergmann L., Hoelzer D.: High expression of ICAM-1 on leucemic cells and upregulation of it’s ligands on lymphocytes by IL-2 in patients with AML. Exp. Hematol. 21, (1993), 1119
  22. Fenchel K., Bergmann L., Engert A., Mitrou P.S., Diehl V., Hoelzer D.: Clinical results and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia – a phase II trial. Ann. Hematol. 67 Suppl. (1993), A30
  23. Fenchel K., Bergmann L., Heller C., Christ S., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Prognostic value of simultaneous expression of CD7 and CD33 on leukemic blasts in AML. Ann. Hematol. Suppl. (1993), A30
  24. Fenchel K., Bergmann L, Heller C., Christ S., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Prognostic value of simultaneous expression of CD7 and CD33 on leukemic blasts in AML. Blood 82 Suppl. (1993), 122a
  25. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical experience and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia – a multicenter trial. Cancer Res. Clin. Oncol. 129 Suppl. (1994) R31
  26. Fenchel K., Bergmann L, Heller C., Willmann E., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Prognostic value of surface expression of CD7, CD33, and CD54 on leukemic blasts in AML. Ann. Hematol. 68 Suppl. 1 (1994), A21
  27. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl, V., Hoelzer D.: Clinical results of fludarabine phosphate in advanced chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Onkol. 17 Suppl. 2, (1994), 33
  28. Fenchel K., Niermann I., v. Illberg C.: Hörsturz infolge Scuba-Tauchens – eine seltene tauchmedizinische Komplikation. Jahrestg. d. Dtsch. Ges. f. HNO, Karlsruhe 29. – 31.05.95
  29. Fenchel K., Winkler A., Neugebauer T., Weidmann E., Mitrou P.S., Hoelzer D., Bergmann L.: Clinical results of two high dose daily alternating schedules with interferon-alpha and interleukin-2 in advanced renal cell cancer and malignant melanoma. 3rd International Symposium “Biological Therapy of Cancer” München, 19. – 22.04.95
  30. Fenchel K., Hinrichs H.F., Anagnou J., Borghardt E.J.: Klinische Ergebnisse nach fraktionierter Gabe von Cisplatin/5-FU bei inoperablen oder rezidivierten Kopf-Halstumoren. 22. Deutscher Krebskongress 20. – 24.02.96 Berlin
  31. Fenchel K., Hinrichs H.F., Anagnou J., Borghardt E.J.: Clinical results and side effects with split course application of cisplatin/5-FU in inoperable and/or recurrent head and neck cancer. Proc. of the American Society of Clinical Oncology ASCO, 15 (1996), 321
  32. Fenchel K., Bergmann L., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical results and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia and non-Hodgkin’s lymphoma. Brit. J. Haematol. 87 Supp. 1, (1994), 167
  33. Fenchel K., Bergmann L., Heller C., Willmann E., Weidmann E., Brieger J., Mitrou P.S., Hoelzer D.: Expression of CD7 and CD15 on leukemic blasts has a positive predictive value for response to induction therapy in AML. Brit. J. Haematol. 87 Supp. 1, (1994), 9
  34. Fenchel K., Atzpodien J., E. J. Borghardt, R.G. Geissler, H. Kirchner, A. Ganser: Fludarabine and Idarubicin followed by IL-2 in the treatment of pretreated advanced indolent lymphoma – preliminary results of a phase II study. Exp. Hematology, 25 (8) (1997), 846
  35. Fenchel K., Anagnou J., Dreher K., Hinrichs H.F., Borghardt E.J.: Klinische Ergebnisse und Nebenwirkungen nach fraktionierter Gabe von Cisplatin/5-FU bei inoperablen oder rezidivierten Kopf-Halstumoren. 6. Interdisziplinäres Onkologisches Symposium, 10. – 12.4.97 Rothenburg o.d.T.
  36. Fenchel K., Atzpodien J., E.J. Borghardt, R.G. Geissler, H. Kirchner, A. Ganser: Combination of Fludarabine, , Idarubicin, and IL-2 in the treatment of pretreated advanced indolent lymphoma – preliminary results of a phase II study. Onkologie, 20, Supp. 1 (1997), 142
  37. Atzpodien J., Fenchel K., R. Hoffmann, E.J. Borghardt, R.G. Geissler, H. Kirchner, A. Ganser: Fludarabine and Idarubicin in the treatment of pretreated advanced indolent lymphoma – results of a phase II study. Blood 90 (10), Supp. 1, 304b
  38. Fenchel K., Atzpodien J., E.J. Borghardt, R.G. Geissler, R. Hoffmann, H. Kirchner, A. Ganser: Interleukin-2 is effective in reducing the Fludarabine-induced CD4+ cell depletion. Blood 90 (10), Supp 1, 511a
  39. Fenchel K., Hoffmann R., Borghardt J., Kirchner H., Pralle H., Ganser A., Atzpodien J.: Interluekin-2 reduces the CD 4+ cell depletion following Fludarabine and Idarubicin combination. Br. J. Haematology 102 (1998), 89
  40. Atzpodien J., Borghardt E., Dreher K., Schrader A., Ganser A., Pralle H., Fenchel K.: Fludarabine and idarubicin followed by IL-2 in pretreated advanced indolent lymphoma: results of a phase II study. Ann. Hematology 77suppl. 1 (1998), A6
  41. Fenchel K., Lassmann S., Borghardt E., Dreher K., Ganser A., Pralle H., Atzpodien J.: Fludarabine and idarubicin followed by IL-2 in the treatment of pretreated advanced indolent lymphoma: results of a phase II study. Ann. Hematology 77suppl. 2 (1998), S147
  42. Fenchel K., Karthaus M., Steffens C., Dreher K., Böhme V., Pralle H., Kubicka S., Weber C., Stoffregen C.: Taxanes: an effective 2nd line treatment of advanced esophageal cancer – a randomised trial. Proc. of the American Society of Clinical Oncology ASCO, 18 (1999), 283a
  43. Fenchel K., Winkler L., Pralle H., Kemkes-Matthes B.: Does therapy with G-CSF in heamatological diseases cause coagulation activation? Proc. 5th international symposium on thrombotic diseases, Cannes, 6/98
  44. Fenchel K., Lassmann S., Borghardt E., Dreher K., Ganser A., Pralle H., Atzpodien J.: Fludarabine and idarubicin followed by IL-2 in the treatment of pretreated advanced indolent lymphoma: results of a phase II study. Ann. Oncology 10 suppl. 3 (1999), 131
  45. Fenchel K., Ehlers S., Matzdorff A., Nees M., Pralle H., Kemkes-Matthes B.: Tissue factor in myeloid leukemia. Ann. Hematolog. (2000) 79suppl. I, A70
  46. Fenchel K., Ehlers S., Winkler L., Pralle H., Kemkes-Matthes B.: Does therapy with G-CSF in haematologic diseases cause coagulation activation? Proc. 6th International symposium on thrombotic diseases, Lisbon, 6/99
  47. Fenchel K., Pralle H.: Prophylaxis of pulmonary mycosis with itraconazole solution in patients undergoing aggressive chemotherapy for AML, M. Hodgkin, NHL, CML and ALL. Proc. 6th internation conference on the management of serious fungal infections, in press
  48. Fenchel K., Goerg A., Matzdorff A., Nees M., Kemkes-Matthes B.: Tissue factor elevation in acute myeloid leukemia: prognostic value for leukemic cells? Blood 96,11 (2000), 201b
  49. Bergmann L., Fenchel K., Jahn B., Mitrou PS.: Up-regulation of adhesion molecules and secondary cytokines in cancer patients treated with bolus infusion II-2. Am. Soc. Cancer Res., San Diego, USA, 20. – 23.5.1992
  50. Bergmann L., Fenchel K., Wijermans P., Engert A., Pralle H., Mitrou P.S., Diehl V., Hoelzer D.: Clinical experience with and immunosuppressive effects of fludarabine phosphate in pretreated advanced chronic lymphocytic leukemia. Onkol. 16 Suppl.1 (1993), 13
  51. Bergmann L., Heil G., Fenchel K., Brücher J., Bunjes D., Lohmeyer J., Gunsilius E., Mitrou P.S.: Interleukin-2 bolus infusion as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologous bone marrow transplantation – biological effects and first clinical results. Ann. Hematol. 64Suppl. (1992), Abstr.87
  52. Göke B., Fenchel K., Knobloch S., Koop I., Adler G., Arnold R.: Influence of asperlicin, a CCK-antagonist, on the trophic response of the rat pancreas to protease-inhibitor feeding. Dig.Dis.Sciences (1987) 32;10:1167
  53. Bergmann L., Fenchel K., Enzinger H.M., Jahn B., Weidmann E., Mitrou P.S.: Daily alternating schedule with interferon-alpha and interleukin-2 in advanced renal cell cancer – clinical results and biological effects. Eur.J.Cancer, 27 Suppl.2 (1991), 100 (Abstr.584)
  54. Jahn B., Weidmann E., Bergmann L., Stock J., Kirsten R., Fenchel K., Mitrou P.S.: Secondary release of cytokines during interleukin-2 therapy in cancer patients. Onkol. 14 Suppl.2 (1991), 190 (Abstr.547)
  55. Bergmann L., Fenchel K., Martin H., Jahn B., Mitrou P.S., Hoelzer D.: Interleukin-2 as late consolidation therapy in 2nd remission of acute myelocytic leukemia with and without autologuous bone marrow transplantation. Onkol. 14 Suppl.2 (1991), 13 (Abstr.31)
  56. Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interleukin-2 inhibits interferon-alpha induced transcription of transforming growth factor-beta1 in vivo. 8. Frühjahrstagung Dtsch. Ges.Immunol., München, 9. – 11.3.1992
  57. Jahn B., Weidmann E., Bergmann L., Fenchel K., Mitrou P.S.: Induction of endogeneous interleukin-2 therapy. J. Cancer Res.Clin.Oncol. 118 (1992), R49
  58. Bergmann L., Fenchel K., Mitrou P.S.: Consecutive studies with dose reduction using a daily alternating schedule of interferon-alpha and interleukin-2 in renal cell cancer. J. Cancer Res. Clin. Oncol. 118 (1992), R116
  59. Bergmann L., Fenchel K., Heil G., Kolbe K., Martin H., Lengfelder E., Bunjes D., Lohmeyer J., Gunsilius E., Mitrou P.S.: Interleukin-2 as late consolidation therapy in 1st relapse of acute myelocytic leukemia – Preliminary results of a multicenter phase II study. Onkol. 15 (1992), Suppl.1, 27
  60. Enzinger H.-M., Bergmann L., Fenchel K., Neugebauer T., Jahn B., Mitrou P.S.: Daily alternating schedules of interferon-alpha and interleukin-2 in advanced renal cell cancer – clinical results and biological effects. Onkol. 15 (1992), Suppl.1, 24
  61. Brieger J., Weidmann E., Fuck S., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: Expression of the wilms tumor gene (wt-1) in human leukemias may provide early detection of minimal residual disease. Ann. Hematol. 67 Suppl. (1993), A15
  62. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The wilms tumor gene (wt-1) mRNA is frequently expressed in AML and may provide early diagnosis of residual blasts. Proc. Am. Ass. Cancer Res. 35 (1994),223
  63. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The wilms tumor gene wt-1 in acute myelogenous leukemia and it’s possible relevance for the patient’s prognosis. Brit. J. Haematol. 87 Suppl. 1, (1994), 4
  64. Mitrou P.S., Enzinger H.-M., Fenchel K., Neugebauer T., Jahn B., Bergmann L.: Clinical results and biological effects of two dose modified daily alternating schedules with interferon-alpha and interleukin-2 in advanced renal cell cancer. Ann. Hematol. 65 Suppl. (1992), A94
  65. Brieger J., Weidmann E., Fenchel K., Fuck S., Mitrou P.S., Bergmann L., Hoelzer D.: The wilms tumor gene as a new possible genetic marker in the detection of minimal residual disease in acute myelogenous leukemia. Cancer Res. Clin. Oncol. 129 Suppl. (1994) R106
  66. Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., Mitrou P.S.: Cloning of peripheral lymphocytes in acute phase of acute myelocytic leukemia results in predominantly CD3+CD4+ T-cell Onkol. 15 (1992), Suppl. 1, 19
  67. Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interferon-alpha (IFN-alpha) induced transcription of transforming growth factor-beta1 (TGF-beta) is Onkol. 15 (1992), Suppl. 1, 25
  68. Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interleukin-2 inhibits interferon-alpha induced transription of transforming growth factor-beta1 in vivo. 8th International Congress of Immunology, Budapest, 23. – 28.8.1992
  69. Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Transforming growth factor-beta1 (TGF-beta1) in vivo: Increase of TGF-beta1 specific mRNA by interferon-alpha (rIFN-alpha) is suppressed by interleukin2 (rll-2) administration. 24th Congess Intern.Soc.Haematol., London, 23-27.8.1992
  70. Bergmann L., Jahn B., Heil G., Kolbe K., Fenchel K., Mitrou P.S.: the effect of interleukin-2 in the consolidation of AML in 2nd remission may be caused by the activation of specific autologous CD4* cytotoxic T-cells 24th Congress Intern.Soc.Haematol., London, 23-27.8.1992
  71. Bergmann L., Karacas T., Jahn B., Lautenschläger G., Szepesi S., Fenschel K., Hoelzer D., Mitrou P.S.: Intensive chemotherapy with vincristine, high-dose adriamycin, cyclophsophamide, prednisone and etoposide (VACPE) in high-malignant non-Hodgkin lymphomas. – An ongoing phase II trial. Ann.Hematol.65 suppl. (1992), A35
  72. Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., P.S. Mitrou: CD3+ CD4+ T-cells as effective cells of autologous blase specific cytotoxicity in acute myelocytic leukemia. Ann.Hematol. 65 Suppl. (1992), A73
  73. Brieger J., Jahn B., Fenchel K., Appelhans, Bergmann L., Mitrou P:S:: Expression of transforming growth factor?1 and interleukin-10 mRNA indicate immunosupresive potential of AML blasts. Ann.Hematol 65 suppl. (1992), A40
  74. Jahn B., Fenchel K., Bergmann L., Mitrou P.S.: Interferon-alpha induced transcription of transforming growth factor-?1 is impaired by interleukin-2 in vivo. Ann.mematol. 65 Suppl. (1992), A73
  75. Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., P.S. Mitrou: Cloning of peripheral lymphocytes in acute phase of acute myelocytic leukemia results in predominantly CD+ CD4+ T-cell clones with blast specific autologous cytotoxicitiy. Blood 80 Suppl. 1 (1992), 188a
  76. Bergmann L., Knuth A., Lautenschläger G., Karacas T., Jahn B., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.,: Intensivierte Chemotherapie mit Voncristin, Hochdosis-Adriblastin, Cyclophosphamid, Prednison und VP-16 (VACPE) bei hochmalignen non-Hodgkin Lymphomen- Zwischenergebnisse einer Phase II Studie Med.Klinik 88 Suppl2 (1993), 215
  77. Bergmann L., Knuth A., Lautenschläger G., Karacas T., Jahn B., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.,: Intensive chemotherapy with a combined therapy of vincristine, high-dose adriamycin, cyclophosphamide, prednisone in high-grade malignant lymphomas. – A phase II study, 5th International Conference on Malignant Lymphoma, Lugano, 9.-12.6.1993
  78. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D.: Inversion of remission duration in 2nd remission of AML by interleukin-2. The antileucemic effect may be caused by autologous CD4+ Cytotoxic lymphocytes. Exp.Hematol. 21, (1993), 1046
  79. Bergmann L., Jahn B., Heil G. Kolbe K., Lengfelder E., Lohmeyer J., Fenchel K., Weidmann E., Mitrou P.S., Hoelzer D.: Inversion of remission duration in 2nd remission of AML by interleukin-2. the antileucemic effect may be caused by autologous CD4+ cyttoxic lymphocytes. Exp.Hematol. 21, (1993), 1046
  80. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: Transforming growth factor transcription and release by AML blasts may indicate immunosuppressive potential. Exp. Hematol. 21, (1993), 1115
  81. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: Transforming growth factor (TGF-?1) transcription and release by leukemic cells may provide an explanation for immunosuppressivion in leukemia. Ann. Hematol. 67 Suppl. (1993), A15
  82. Mitrou P.S., Jahn B., Bergmann L., Fenchel K., Weidmann E., Schwulera U., Hoelzer D.: Cloning of peripheral lymphocytes in untreated acute myelocytic leukemia results in predominantly CD3+ CD4+ T-cell clones with blast specific autologous cytotoxicitiy. Ann. Hematol. 67 Suppl. (1993), A82
  83. Weidmann E., Brieger J., Fenchel., Hoelzer D., Bergmann L., Mitrou P.S.: Introduction of a model to study the in vitro T-cell response to autologous cytokine gene engineered tumor cells. Ann. Hematol. 67 Suppl. (1993), A82
  84. Bergmann L., Karacas T., Knuth A., Lautenschläger G., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.: Effective chemotherapy with a combined therapy of vincristine, adriamycin, cyclophsophamide, prednisone and etoposide (VACPE) in high-grade non-hodgkin lymphomas. – Results of a phase II study. Ann Hematol. 67 Suppl. (1993), A9
  85. Bergmann L., Karacas T., Knuth A., Lautenshcläger G., Szepesi S., Fenchel K., Mitrou P.S., Hoelzer D.: Combined therapy with vincristine, Adriamycin, cyclophsophamide, prednisone and etoposide (VACPE) in high-grade malignant lymphomas. – Results of a phase II study. Cancer Res. Clin. Oncol. 129 Suppl. (1994) R31
  86. Weidmann E., Brieger J., Fenchel K., Mitrou P.S., Bergmann L., Holezer D.: Expression of the IL-2 receptor alpha, beta, gamma chains on AML blasts and on AML derived cell lines. Proc. Am. Ass. Cancer Res. 35 (1994), 531
  87. Schui D.K., Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The inhibition of the lymphokine activated killer cells activation meidated by AML culture supernatants might be due to transfomring growth factor beta (TGF-ß1). Ann. Hematol. 68 Suppl. 1 (1994), A37
  88. Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Bergmann L., Hoelzer D.: The amplification of the wilms tumor gene (wt-1) mRNA using the polymerase chain reaction technique (PCR) may enable sensitive detection of small blast populations in AML. Ann. Hematol. 68 Suppl. 1 (1994), A16
  89. Weidmann E., Brieger J., Fenchel K., Hoelzer D., Bergmann L., Mitrou P.S.: IL-2 receptor (IL-2R)alpha, beta, gamma chains expressed on blasts of acute myelocytic leukemia may not be functional. Ann. Hematol. 68 Suppl. 1 (1994), A21
  90. Weidmann E., Brieger J., Jahn B., Fenchel K., Bergmann L., Hoelzer D., Mitrou P.S.: Analysis of lymphocyte mediated cytotoxic activity against blast cells from acute myelocytic leukemia by blast cell lactate dehydrogenase release. Brit. J. Haematol. 87 Suppl. 1, (1994), 23
  91. Schui D. K., Brieger J., Weidmann E., Fenchel K., Mitrou P.S., Hoelzer D., Bergmann L.: TGF-beta1 might be responsible for the inhibition of LAK activity mediated by blast cell culture supernatants. Brit. J. Haematol. 87 Suppl. 1, (1994), 20
  92. Brieger J., WEidmann E., Fuck S., Fenchel K., Bergmann L., Hoelzer D., Mitrou P.S.: Unresponsiveness to IL-2 by AML blast cells expressing IL-2 receptors. Onkol. 17 Suppl. 2, (1994), 17
  93. Borghardt E.J., Kirchertz E.J., Marten I., Fenchel K.: Protein A-immunoadsorption in chemotherapy associated hemolytic-uremic syndrome. Kongreß Dresden 4/97
  94. Karthaus M., Rosenthal C., Paul H., Novotny J., Hübner G., Fenchel K. Geissler RG., Hertenstein B., Ganser A.: Effect of topical oral G-CSF application on oral mucositis in high-grade lymphoma patients treated with HD-methotrexate (HD-MTX) – results of a randomized placebo-controlled trial. Proc. of the American Society of Clinical Oncology ASCO, 17 (1998), 61a
  95. Georg A., Matzdorff A., Fenchel K., Kemkes-Matthes B., Pralle H.: Quantification of tissue factor antigen expression on monocytes and neutrophils in healthy volunteers and in AML patients. Blood 96,11 (2000), 75b
  96. Georg A., Matzdorff A., Fenchel K., Kemkes-Matthes B., Pralle H.: Quantification of tissue factor antigen expression on monocytes and neutrophils in healthy volunteers and in AML patients. Blood 96, 11 (2000), 75b
  97. Aldulak-Tursun C., Fenchel K., Matzdorff A., Pralle H., Kemkes-Matthes B.: Frequency of thromboembolic complications in cancer patients. GTH, Freiburg 2001
  98. Rudolph S., Fahlke J., Kuhn R., Fenchel K., Lippert H., Ridwelski K.: Randomised trial with or without Amifostine to reduce neurotoxic side effects under chemotherapy with Oxaliplatin (L-OHP), FA/5-FU. Proc. of the American Society of Clinical Oncology ASCO, 20 (2001), 302b
  99. Peinert S., Abenhardt W., Fenchel K., Hübner A., Paulsen M., Reichert D., Scheidegger C., Schmidt A., von Wussow P., Galic M.: A prospective multicenter safety surveillance study with a 5% intravenous human immunoglobulin (IVIg) preparation, in patients suitable for IVIg treatment, with or without prophylaxis prior to infusion. presented at DGHO Leipzig 14.-18.10.2016
  100. Grabowski C., Hoyer M., Fenchel K., Kroll H.: Frequency of in a patient. DGTI, Nürnberg 7.-10.9.2016
  101. Manz K, Fenchel K., Eilers A, Morgan J., Wittling K., Dempke W., Efficacy and safety of approved first-line tyrosine kinase inhibitor (TKI) treatment in patients with metastatic renal cell carcinoma (mRCC): A network meta-analysis based on phase II/III randomised clinical trials (RCTs). Presented at ASCO 2019, J Clin Oncol 37 (Suppl), e16074 (2019)
  102. Fenchel K., Fenchel S., Dempke W., Winkler C.: Single center experience with Rucaparib after prior line PARPi treatment in relapsed ovarian cancer patients DGHO Basel 2020 ID 585
  103. Fenchel K., Fenchel S., Dempke W., Hager D., Walter J., Winkler C.: Monozentrische Ergebnisse mit Abemaciclib bei MammaCa-Patientinnen mit ungünstiger Prognose im Relaps nach vorheriger Behandlung mit Palbociclib Single center experience with Rucaparib after prior line PARPi treatment in relapsed ovarian cancer patients“ DGHO Basel 2020 ID 643
  104. Gerger, A; Eisterer, W; Fuxius, S; Bastian, S; Köberle, D; Welslau, M; Akhoundova, D; Maas, C; Uhlig, J; Fenchel, K; Greil, R; von der Heyde, E; Rhyner, G; Weide, R; Modest, DP; Fritsch, RM.: Retrospective analysis of treatment pathways in patients with BRAFV600E-mutant metastatic colorectal carcinoma -MORSECRC DGHO Basel 2020 ID 339
  105. Kohlbrenner K., Galuschek N., Fabarius A., Reiser M., Fenchel K., Eßeling E., Göhler T., Kühn R.B., Depenbusch R., Azeh I., Kleeberg U.R., Hansen R., Hänel M., Anhuf J., Jehner P., Baerlocher G.M., Brümmendorf T.H., Heim D., Krause S.W., le Coutre P., Neubauer A., Niederwieser D., Tesch H., Hochhaus A., Hehlmann R., Saußele S.: Discontinuation of tyrosine kinase inhibitor therapy in CML patients outside of clinical trials: Interim results of the German CML VI trial DGHO Berlin 2021
  106. Wang S. Y, Holzhey T., Heyn S., Zehrfeld T., Fricke S., Hoffmann F.A., Becker C., Braunert L., Edelmann T., Paulenz I., Hitschke M., Flade F., Schwarzer A., Fenchel K., Franke G., Vucinic V., Jentzsch M., Schwind S., Lange T., Niederwieser D., Platzbecker U., Pönisch W.: Impact of the changing landscape of induction therapy prior to autologous stem cell transplantation in 540 myeloma patients: a retrospective real-world study. IMW International Myeloma Group Vienna 8.-11.Sept. 2021 Abstract ID:1052254
  107. Kohlbrenner K., Galuschek N., Fabarius A., Reiser M., Fenchel K., Eßeling E., Göhler T., Kühn R.B., Depenbusch R., Azeh I., Kleeberg U.R., Hansen R., Hänel M., Anhuf J., Jehner P., Baerlocher G.M., Brümmendorf T.H., Heim D., Krause S.W., le Coutre P., Neubauer A., Niederwieser D., Tesch H., Hochhaus A., Hehlmann R., Saußele S.: Discontinuation of tyrosine kinase inhibitor therapy in CML patients outside of clinical trials: Interim results of the Gean CML VI trial „ ASH New Orleans 2022 Abstract 390 oral presentation Dec.10 17:15
  108. Kohlbrenner K., Galuschek N., Fabarius A., Reiser M., Fenchel K., Eßeling E., Göhler T., Kühn R.B., Depenbusch R., Azeh I., Kleeberg U.R., Hansen R., Hänel M., Anhuf J., Jehner P., Baerlocher G.M., Brümmendorf T.H., Heim D., Krause S.W., le Coutre P., Neubauer A., Niederwieser D., Tesch H., Hochhaus A., Hehlmann R., Saußele S.: ELN Treatment Milestones in CML Are Prognostic for Achieving DMR and TFR in Routine Care: Results of the German CML Registry. ASH San Diego 2023 Abstract Poster Presentation
  109. Kohlbrenner K., Galuschek N., Fabarius A., Reiser M., Fenchel K., Eßeling E., Göhler T., Kühn R.B., Depenbusch R., Azeh I., Kleeberg U.R., Hansen R., Hänel M., Anhuf J., Jehner P., Baerlocher G.M., Brümmendorf T.H., Heim D., Krause S.W., le Coutre P., Neubauer A., Niederwieser D., Tesch H., Hochhaus A., Hehlmann R., Saußele S.: European LeukemiaNet milestones and their prognostic relevance for achieving deep molecular response and treatment-free remission in routine care: results of the German CML Registry: EHA 2024
  110. Fenchel K., Dempke W., Jobst B., Jobst C., Jobst F., Winkler C.: Monozentrische Ergebnisse mit Abemaciclib bei Mammakarzinom-Patientinnen mit ungünstiger Prognose im Relaps nach vorheriger Behandlung mit CDK4/6i. 57. Fortbildungstagung für Gynäkologie & Geburtshilfe 3.-7.2.2025 Obergurgl, Österreich
  111. Fenchel K., Dempke W., Jobst B., Jobst C., Jobst F., Winkler C.: Monozentrische Ergebnisse mit Abemaciclib bei Mammakarzinom-Patientinnen mit ungünstiger Prognose im Relaps nach vorheriger Behandlung mit CDK4/6i. ACE+ Conference 21.-22.03.2025 Frankfurt/M.
  112. Fenchel K, von der Heyde E., Zaiss M., Illmer T., Schulze M., Schroeder S., Kummer D., Jäger S, Marschner P.: Real-World Incidence of Bleeding Events in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib +/- Obinutuzumab and Requiring Direct Oral Anticoagulation , ASH2025, Orlando
  113. Fenchel K., Geuther G., Dempke W.: Successful Melphalan Fluflenamide (Melflulen) Therapy in Patients with Severe Renal Insufficiency, ASH2025, Orlando
  114. Fenchel K, von der Heyde E., Zaiss M., Illmer T., Schulze M., Schroeder S., Kummer D., Jäger S, Marschner P.: Real-World Incidence of Bleeding Events in Patients with Chronic Lymphocytic Leukemia Treated with Acalabrutinib +/- Obinutuzumab and Requiring Direct Oral Anticoagulation, DKK2026 Berlin